| Original language | English (US) |
|---|---|
| Pages (from-to) | 1488-1489 |
| Number of pages | 2 |
| Journal | Movement Disorders |
| Volume | 35 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2020 |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Inconsistent Movement Disorders Society–Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative. / Turner, Travis H.; Dale, Marian L.
In: Movement Disorders, Vol. 35, No. 8, 01.08.2020, p. 1488-1489.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Inconsistent Movement Disorders Society–Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative
AU - Turner, Travis H.
AU - Dale, Marian L.
N1 - Funding Information: Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi- info.org/data). For up-to-date information on the study, visitwww.ppmi- info.org. PPMI—a public–private partnership—is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Allergan, Amathus therapeutics, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Meyers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, Ucb, Verily, and Voyager Therapeutics. Funding Information: Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database ( www.ppmi ‐ info.org/data ). For up‐to‐date information on the study, visit www.ppmi ‐ info.org . PPMI—a public–private partnership—is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Allergan, Amathus therapeutics, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol‐Meyers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, Ucb, Verily, and Voyager Therapeutics.
PY - 2020/8/1
Y1 - 2020/8/1
UR - http://www.scopus.com/inward/record.url?scp=85084808506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084808506&partnerID=8YFLogxK
U2 - 10.1002/mds.28108
DO - 10.1002/mds.28108
M3 - Letter
C2 - 32424978
AN - SCOPUS:85084808506
SN - 0885-3185
VL - 35
SP - 1488
EP - 1489
JO - Movement Disorders
JF - Movement Disorders
IS - 8
ER -